Edwards Lifesciences upgraded to Outperform from Market Perform at JMP Securities JMP Securities upgraded Edwards Lifesciences to Outperform from Market Perform and established a $97 price target. The firm upgraded shares following positive survey results that indicate TAVI volumes will continue to grow 30%+, the approval of Sapien XT will shift market share back to Edwards and growth is coming from larger valve sizes and smaller sheaths.
News For EW From The Last 14 Days
Check below for free stories on EW the last two weeks.
Edwards Lifesciences price target raised to $120 from $95 at Piper Jaffray Piper Jaffray raised its price target for Edwards Lifesciences shares to $120 saying recent Transcatheter Aortic Valve Replacement market momentum is likely to continue. The firm keeps an Overweight rating on the stock.
Edwards Lifesciences price target raised to $114 from $103 at Canaccord Canaccord raised its price target on Edwards Lifesciences to $114 from $103 following positive updates on the SAPIEM franchise and on the heels of several positive trends and upside surprises across the businesses during the quarter. Canaccord maintains its Buy rating on the stock.